Breast Cancer

Nivolumab plus ipilimumab induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Aromatase inhibitors may reduce breast cancer recurrence compared with tamoxifen for certain postmenopausal women with breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Race did not significantly predict response to treatment outcomes among women with high-risk breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to first-line chemotherapy conferred clinically meaningful benefit to patients with inoperable or metastatic triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Metformin did not improve outcomes for most patients with early breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The addition of entinostat to exemestane improved PFS for patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended EFS for patients with early triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol 3-kinase pathway mutations than those with de novo cases, according to results presented at San Antonio Breast Cancer Symposium.

Imaging mass cytometry appeared feasible and allowed for a more comprehensive overview of triple-negative breast cancer heterogeneity at a single-cell level, according to study results presented at San Antonio Breast Cancer Symposium.

Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.